OXIGENE'S CA4P TO ENTER MULTICENTER CLINICAL TRIAL

OXiGENE is initiating a Phase II clinical trial evaluating its lead vascular disrupting agent, Combretastatin A4 Phosphate (CA4P), in triple combination therapy with carboplatin and paclitaxel -- a widely used chemotherapeutic regimen -- for the treatment of relapsed, advanced platinum-resistant ovarian cancer.

The trial will be an international, open-label trial designed to determine the safety and efficacy of CA4P in combination with carboplatin and paclitaxel. It will be a multicenter study. OXiGENE expects the study to be initiated at cancer centers in the UK and the U.S.